| Autor: |
Ralph G, Brindis, Pamela S, Douglas, Robert C, Hendel, Eric D, Peterson, Michael J, Wolk, Joseph M, Allen, Manesh R, Patel, Ira E, Raskin, Timothy M, Bateman, Manuel D, Cerqueira, Raymond J, Gibbons, Linda D, Gillam, John A, Gillespie, Ami E, Iskandrian, Scott D, Jerome, Harlan M, Krumholz, Joseph V, Messer, John A, Spertus, Stephen A, Stowers |
| Jazyk: |
angličtina |
| Předmět: |
|
| Zdroj: |
Journal of the American College of Cardiology. (8):1587-1605 |
| ISSN: |
0735-1097 |
| DOI: |
10.1016/j.jacc.2005.08.029 |
| Popis: |
Under the auspices of the American College of Cardiology Foundation (ACCF) and the American Society of Nuclear Cardiology (ASNC), an appropriateness review was conducted for radionuclide cardiovascular imaging (RNI), specifically gated single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI). The review assessed the risks and benefits of the imaging test for several indications or clinical scenarios and scored them based on a scale of 1 to 9, where the upper range (7 to 9) implies that the test is generally acceptable and is a reasonable approach, and the lower range (1 to 3) implies that the test is generally not acceptable and is not a reasonable approach. The mid range (4 to 6) implies that the test may be generally acceptable and may be a reasonable approach for the indication. The indications for this review were primarily drawn from existing clinical practice guidelines and modified based on discussion by the ACCF Appropriateness Criteria Working Group and the Technical Panel members who rated the indications. The method for this review was based on the RAND/UCLA approach for evaluating appropriateness, which blends scientific evidence and practice experience. A modified Delphi technique was used to obtain first- and second-round ratings of 52 clinical indications. The ratings were done by a Technical Panel with diverse membership, including nuclear cardiologists, referring physicians (including an echocardiographer), health services researchers, and a payer (chief medical officer). These results are expected to have a significant impact on physician decision making and performance, reimbursement policy, and future research directions. Periodic assessment and updating of criteria will be undertaken as needed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
